Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-28T07:17:25.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparative study of efficacy and toxicities of cisplatin vs vinorelbine as radiosensitisers in locally advanced head and neck cancer

Published online by Cambridge University Press:  20 April 2007

S K Sarkar ,
N B Patra ,
J Goswami  and
S Basu
S K Sarkar*
Affiliation:
Department of Radiotherapy, Medical College Hospital, Kolkata, India
N B Patra
Affiliation:
Department of Radiotherapy, Medical College Hospital, Kolkata, India
J Goswami
Affiliation:
Department of Radiotherapy, Medical College Hospital, Kolkata, India
S Basu
Affiliation:
Department of Radiotherapy, Medical College Hospital, Kolkata, India
*
Address for correspondence: Dr (Prof) Shyamal Kumar Sarkar, 80/1E Kankulia Road, Kolkata 700029, India. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Currently, concomitant chemoradiation using cisplatin is one of the standards of care for the management of head and neck cancer, but at the cost of increased acute toxicity. Our aim was to assess whether vinorelbine was less toxic and of at least comparable efficacy, if not better, compared with cisplatin.

Materials and methods:

A total of 72 patients with squamous cell carcinoma in the head and neck region were recruited, 40 in arm A and 32 in arm B. Patients in arm A received 40 mg/m2 cisplatin weekly. Patients in arm B received 6 mg/m2 vinorelbine weekly. Both arms also received 66 Gy of radiation in conventional fractionation.

Results and analysis:

There was no statistically significant difference in response rate or toxicities between the two arms, except for nausea and/or vomiting, which was significantly less frequent in the vinorelbine arm.

Conclusion:

Vinorelbine was as effective as cisplatin in controlling locoregional disease in locally advanced head and neck cancer, but was only marginally less toxic than cisplatin.

Keywords

ChemoradiationHead and Neck CancerToxicity, Concomitant
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 122 , Issue 2 , February 2008 , pp. 188 - 192
Copyright
Copyright © JLO (1984) Limited 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Brizel, DM. The role of combined radiation therapy and chemotherapy in the management of locally advanced squamous cell carcinoma of the head and neck. In: Perez, CA, Brady, LW, Halperin, EC, Schmidt-Ullrich, RK. Principles and Practice of Radiation Oncology, 4th edn. Philadelphia: Lippincot Williams & Wilkins, 2004;905–16Google Scholar
2 Pignon, JP, Bourhis, J, Domenge, C, Designe, L, on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949–55CrossRefGoogle ScholarPubMed
3 Eschwege, F, Sancho Garnier, H, Gerard, JP, Madelain, M, DeSaulty, A, Jortay, A et al. Ten year result of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: experience of the European Organization for Research and Treatment for Cancer. Natl Cancer Inst Monogr 1988;6:275–8Google Scholar
4 Fu, KK, Philips, TL, Silverberg, IJ, Jacobs, C, Goffinet, DR, Chun, C et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410–18CrossRefGoogle ScholarPubMed
5 Browman, GP, Hodson, DI, MacKenzie, RJ, Bestic, N, Zuraw, L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579–89CrossRefGoogle ScholarPubMed
6 Sanchiz, F, Milla, A, Turner, J, Bonet, F, Artola, N, Carreno, L et al. Single fraction/day vs. two fractions/day vs. radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347–50CrossRefGoogle Scholar
7 Browmann, GP, Crips, C, Hodson, DI, Eapen, L, Sathya, J, Levine, MN et al. Placebo-controlled randomized trial of infusional 5-FU during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:2648–53CrossRefGoogle Scholar
8 Smid, L, Lesnicar, H, Zacotnik, B, Soba, E, Budinha, M, Furlan, L et al. Radiotherapy combined with simultaneous chemotherapy mitomycin C and bleomycin for inoperable head and neck cancer: preliminary report. Int J Radiat Oncol Biol Phys 1995;32:769–75CrossRefGoogle ScholarPubMed
9 Bachaud, JM, Cohen, JE, Alzien, C, David, JM, Serrano, E, Daly-Schveitzer, N. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck cancer: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999–1004CrossRefGoogle Scholar
10 Merlano, M, Benamo, M, Corvo, R, Rosso, R, Vitale, V, Blengio, F et al. Five year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of head and neck. J Natl Cancer Inst 1996;88:583–9CrossRefGoogle Scholar
11 Brizel, DM, Albers, ME, Fisher, SR, Scher, RL, Richtsmeier, WJ, Hars, V et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798–804CrossRefGoogle ScholarPubMed
12 Wendt, TG, Grabenbauer, GG, Rodel, CM, Thiel, HJ, Aydin, H, Rohloff, R et al. Simultaneous radiochemotherapy vs radiotherapy alone in advanced head and neck cancer: a randomized multicentre study. J Clin Oncol 1998;16:1318–24CrossRefGoogle Scholar
13 Jeremic, B, Shibamoto, Y, Milicic, B, Nikolic, N, Dagovic, A, Aleksandrovic, J et al. Hyperfractionated radiation therapy with or without concurrent low dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458–64CrossRefGoogle ScholarPubMed
14 Adelstein, DJ, Li, Y, Adams, GL, Wagner, H, Kish, JA, Ensley, JF et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92–8CrossRefGoogle ScholarPubMed
15 Munro, AJ. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83–91CrossRefGoogle ScholarPubMed
16 El-Sayed, S, Nelson, N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838–47CrossRefGoogle ScholarPubMed
17 Weissberg, JB, Son, YH, Papac, RJ, Sasaki, C, Fischer, DB, Lawrence, R et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989;17:3–9CrossRefGoogle ScholarPubMed